Carolyn J Crandall1, Aaron Aragaki, Jane A Cauley, JoAnn E Manson, Erin LeBlanc, Robert Wallace, Jean Wactawski-Wende, Andrea LaCroix, Mary Jo O'Sullivan, Mara Vitolins, Nelson B Watts. 1. Department of Internal Medicine (C.J.C.), David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California 90095; Women's Health Initiative Clinical Coordinating Center (A.A.), Fred Hutchinson Cancer Research Center, Seattle, Washington 98109; Department of Epidemiology (J.A.C.), Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania 15213; Division of Preventive Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115; Center for Health Research NW (E.L.), Kaiser Permanente, Portland, Oregon 97227; Department of Epidemiology (R.W.), University of Iowa College of Public Health, Iowa City, Iowa 52242; Department of Epidemiology and Environmental Health (J.W.-W.), University at Buffalo, State University of New York, Buffalo, New York 14214; Public Health Sciences (A.L.), Fred Hutchinson Cancer Research Center, Seattle, Washington 98109; Department of Obstetrics and Gynecology (M.J.O'S.), Miller School of Medicine, University of Miami, Miami, Florida 33136; Department of Epidemiology and Prevention (M.V.), Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, North Carolina 27157; and Mercy Health Osteoporosis and Bone Health Services (N.B.W.), Cincinnati, Ohio 45236.
Abstract
CONTEXT: Vasomotor symptoms (VMS) are common. Whether VMS are associated with fracture incidence or bone mineral density (BMD) levels is unknown. OBJECTIVE: This study aimed to examine associations of baseline VMS with fracture incidence and BMD. DESIGN: This was a prospective observational study with mean (SD) followup of 8.2 (1.7) years (1993-2005). SETTING: Forty United States clinical centers. PARTICIPANTS: We examined data from Women's Health Initiative Clinical Trial participants (n = 23 573) age 50-79 years not using menopausal hormone therapy, and 4,867 participants of the BMD sub-study. INTERVENTIONS: None. MAIN OUTCOME MEASURES: We measured baseline VMS, incident adjudicated fractures, and BMD (baseline, annual visits 1, 3, 6, and 9). RESULTS: After adjustment for baseline age, body mass index, race/ethnicity, smoking, and education, the hazard ratio for hip fracture among women with baseline moderate/severe VMS (vs no VMS) was 1.78 (95% confidence interval [CI], 1.20-2.64; P = .01). There was no association between VMS and vertebral fracture. VMS severity was inversely associated with BMD during followup (P = .004 for femoral neck, P = .045 for lumbar spine). In repeated measures models, compared with women who reported no VMS, women with moderate/severe VMS had 0.015 g/cm(2) lower femoral neck BMD (95% CI, -0.025--0.005) and 0.016 g/cm(2) lower lumbar spine BMD (95% CI, -0.032--0.004). CONCLUSIONS: Women with moderate/severe VMS have lower BMD and increased hip fracture rates. Elucidation of the biological mechanisms underlying these associations may inform the design of preventive strategies for at-risk women prior to occurrence of fracture.
CONTEXT: Vasomotor symptoms (VMS) are common. Whether VMS are associated with fracture incidence or bone mineral density (BMD) levels is unknown. OBJECTIVE: This study aimed to examine associations of baseline VMS with fracture incidence and BMD. DESIGN: This was a prospective observational study with mean (SD) followup of 8.2 (1.7) years (1993-2005). SETTING: Forty United States clinical centers. PARTICIPANTS: We examined data from Women's Health Initiative Clinical Trial participants (n = 23 573) age 50-79 years not using menopausal hormone therapy, and 4,867 participants of the BMD sub-study. INTERVENTIONS: None. MAIN OUTCOME MEASURES: We measured baseline VMS, incident adjudicated fractures, and BMD (baseline, annual visits 1, 3, 6, and 9). RESULTS: After adjustment for baseline age, body mass index, race/ethnicity, smoking, and education, the hazard ratio for hip fracture among women with baseline moderate/severe VMS (vs no VMS) was 1.78 (95% confidence interval [CI], 1.20-2.64; P = .01). There was no association between VMS and vertebral fracture. VMS severity was inversely associated with BMD during followup (P = .004 for femoral neck, P = .045 for lumbar spine). In repeated measures models, compared with women who reported no VMS, women with moderate/severe VMS had 0.015 g/cm(2) lower femoral neck BMD (95% CI, -0.025--0.005) and 0.016 g/cm(2) lower lumbar spine BMD (95% CI, -0.032--0.004). CONCLUSIONS:Women with moderate/severe VMS have lower BMD and increased hip fracture rates. Elucidation of the biological mechanisms underlying these associations may inform the design of preventive strategies for at-risk women prior to occurrence of fracture.
Authors: Tonya S Orchard; Joseph C Larson; Nora Alghothani; Sharon Bout-Tabaku; Jane A Cauley; Zhao Chen; Andrea Z LaCroix; Jean Wactawski-Wende; Rebecca D Jackson Journal: Am J Clin Nutr Date: 2014-02-05 Impact factor: 7.045
Authors: Jacques E Rossouw; Ross L Prentice; JoAnn E Manson; Lieling Wu; David Barad; Vanessa M Barnabei; Marcia Ko; Andrea Z LaCroix; Karen L Margolis; Marcia L Stefanick Journal: JAMA Date: 2007-04-04 Impact factor: 56.272
Authors: Douglas W Levine; Robert M Kaplan; Daniel F Kripke; Deborah J Bowen; Michelle J Naughton; Sally A Shumaker Journal: Psychol Assess Date: 2003-06
Authors: Carolyn J Crandall; Chi-Hong Tseng; Arun S Karlamangla; Joel S Finkelstein; John F Randolph; Rebecca C Thurston; Mei-Hua Huang; Huiyong Zheng; Gail A Greendale Journal: J Clin Endocrinol Metab Date: 2013-02-26 Impact factor: 5.958
Authors: Robert D Langer; Emily White; Cora E Lewis; Jane M Kotchen; Susan L Hendrix; Maurizio Trevisan Journal: Ann Epidemiol Date: 2003-10 Impact factor: 3.797
Authors: A Z LaCroix; T J Beck; J A Cauley; C E Lewis; T Bassford; R Jackson; G Wu; Z Chen Journal: Osteoporos Int Date: 2009-09-15 Impact factor: 4.507
Authors: Gerrie-Cor M Gast; Diederick E Grobbee; Victor J M Pop; Jules J Keyzer; Colette J M Wijnands-van Gent; Göran N Samsioe; Peter M Nilsson; Yvonne T van der Schouw Journal: Menopause Date: 2009 Mar-Apr Impact factor: 2.953
Authors: Carolyn J Crandall; Yan Zheng; Sybil L Crawford; Rebecca C Thurston; Ellen B Gold; Janet M Johnston; Gail A Greendale Journal: Menopause Date: 2009 Mar-Apr Impact factor: 2.953
Authors: Maria Almeida; Michaël R Laurent; Vanessa Dubois; Frank Claessens; Charles A O'Brien; Roger Bouillon; Dirk Vanderschueren; Stavros C Manolagas Journal: Physiol Rev Date: 2017-01 Impact factor: 37.312
Authors: Carolyn J Crandall; JoAnn E Manson; Chancellor Hohensee; Steve Horvath; Jean Wactawski-Wende; Erin S LeBlanc; Mara Z Vitolins; Rami Nassir; Janet S Sinsheimer Journal: Menopause Date: 2017-03 Impact factor: 2.953
Authors: Carolyn J Crandall; Joseph Larson; Jane A Cauley; John T Schousboe; Andrea Z LaCroix; John A Robbins; Nelson B Watts; Kristine E Ensrud Journal: JBMR Plus Date: 2019-11-30
Authors: Evelyn M M Wong; George Tomlinson; Marsha M Pinto; Claudie Berger; Angela M Cheung; Jerilynn C Prior Journal: Int J Environ Res Public Health Date: 2018-05-26 Impact factor: 3.390